🔓 Unlock the full profile of Ivan Uthup (Hikal Ltd), including verified contact details, financial insights, and professional associations.

See Ivan Uthup Full Profile

Below are the ✅ Verified Contact Details to help you connect directly:

Email: iva*****@hik******.com

Mobile: 65265*****

Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)

Key Insights You Should Know About This Individual

  • Ivan Uthup is set to become the Founder of Hemodos Pharmaceuticals starting July 1, 2024, indicating an entrepreneurial venture into the pharmaceutical industry.
  • Before this role, Ivan served as the Deputy Manager - API Exports for Hikal Ltd from October 2021 to June 2024, focusing on the Europe, USA, and Canada regions, contributing to the company's international sales strategy.
  • At Hikal Ltd, Ivan was instrumental in expanding the company’s reach and establishing strong relationships with clients in multiple regions.
  • Previously, Ivan worked at Ipca Laboratories Limited as the Assistant Manager - API Exports (Europe region) from December 2020 to September 2021, where responsibilities included overseeing export operations and enhancing market presence.
  • Prior to this, Ivan contributed to Molkem as a Senior International Sales Executive from March 2019 to December 2020, focusing on international sales and marketing initiatives.
  • Ivan’s career began as an International Sales Executive at Molkem (March 2018 to March 2019), where foundational skills in international sales were developed.
  • In earlier roles, Ivan functioned as a Business Development Manager at Micro Labs Ltd from January 2017 to February 2018 and as an International Management Trainee at Claris Lifesciences Limited from May 2016 to December 2016, showcasing growth through various business development and management roles.
  • Ivan's journey in the pharmaceutical industry reflects progressive responsibilities and a strong emphasis on international sales and export management, culminating in the upcoming leadership role at Hemodos Pharmaceuticals.